carboplatin + mitoxantrone + thiotepa

Based on the search results, I'll provide comprehensive information about the combination drug "carboplatin + mitoxantrone + thiotepa". This combination appears to be a high-dose chemotherapy regimen used primarily in cancer treatment, particularly for lymphomas, breast cancer, and inflammatory breast cancer. The search results show it has been studied in clinical trials and used in autologous stem cell transplantation settings. The combination is sometimes referred to as "TMJ" regimen (Thiotepa, Mitoxantrone, and carboplatin (J))[1][4]. It has been used as a conditioning regimen before autologous stem cell transplantation in patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL)[1], and inflammatory breast cancer[4]. ## Dosing Information The typical dosing regimen appears to be: - Thiotepa: 250 mg/m² once daily intravenously for 3 days - Mitoxantrone: 40 mg/m² for 1 day - Carboplatin: 333 mg/m² once daily intravenously for 3 days[4] ## Clinical Efficacy The combination has shown efficacy in several clinical settings: 1. In patients with Hodgkin's disease and non-Hodgkin's lymphoma, with a median follow-up of 91 months, the median survival was 107 months and the 5-year disease-free survival was 43%[1]. 2. In inflammatory breast cancer (IBC), the regimen was well-tolerated compared to prior regimens that included carmustine or cisplatin[4]. 3. The treatment-related mortality appears to be relatively low at around 4% in some studies[1]. ## Toxicity Profile Common toxicities associated with this regimen include: - Mucositis and enteritis (major non-hematologic toxicities)[2] - Delayed myelosuppression[2] - Central nervous system toxicity (dose-limiting)[2] - Acute renal failure (dose-limiting)[2] This combination represents a high-dose chemotherapy approach that is typically used in conjunction with autologous stem cell rescue/transplantation to manage the significant myelosuppression that occurs with these dose-intensive regimens.